PE20171181A1 - Complejos radiofarmaceuticos - Google Patents
Complejos radiofarmaceuticosInfo
- Publication number
- PE20171181A1 PE20171181A1 PE2017001093A PE2017001093A PE20171181A1 PE 20171181 A1 PE20171181 A1 PE 20171181A1 PE 2017001093 A PE2017001093 A PE 2017001093A PE 2017001093 A PE2017001093 A PE 2017001093A PE 20171181 A1 PE20171181 A1 PE 20171181A1
- Authority
- PE
- Peru
- Prior art keywords
- chelator
- thorium
- refers
- tissue
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se refiere a un metodo para la formacion de un complejo radiofarmaceutico de torio dirigido a tejido, en donde dicho metodo comprende: a) formar un quelante octadentado que comprende cuatro porciones hidroxipiridinona (HOPO) sustituidas en la posicion N con un grupo C1-C3 alquilo, y una porcion de acoplamiento que termina en un grupo acido carboxilico; b) acoplar dicho quelante octadentado a por lo menos un peptido o proteina de direccionamiento a tejido que comprende por lo menos una porcion amina por medio de por lo menos un reactivo de acoplamiento de amida para generar asi un quelante de direccionamiento a tejido; y c) poner en contacto dicho quelante con una solucion acuosa que comprende un ion de por lo menos un isotopo de torio emisor alfa. Tambien se refiere a un complejo de torio y a una formulacion farmaceutica que la comprende, para el tratamiento de una enfermedad neoplasica e hiperplasica
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422512 | 2014-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171181A1 true PE20171181A1 (es) | 2017-08-22 |
Family
ID=54884033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001093A PE20171181A1 (es) | 2014-12-17 | 2015-12-15 | Complejos radiofarmaceuticos |
| PE2022002504A PE20230829A1 (es) | 2014-12-17 | 2015-12-15 | Complejos radiofarmaceuticos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002504A PE20230829A1 (es) | 2014-12-17 | 2015-12-15 | Complejos radiofarmaceuticos |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20170340759A1 (es) |
| EP (1) | EP3233137A1 (es) |
| JP (2) | JP6821569B2 (es) |
| KR (1) | KR20170094223A (es) |
| CN (1) | CN107278155B (es) |
| AR (1) | AR103063A1 (es) |
| AU (2) | AU2015367722A1 (es) |
| BR (1) | BR112017012841A2 (es) |
| CA (1) | CA2970841A1 (es) |
| CL (1) | CL2017001592A1 (es) |
| CO (1) | CO2017005975A2 (es) |
| CR (1) | CR20170256A (es) |
| CU (1) | CU24493B1 (es) |
| DO (1) | DOP2017000143A (es) |
| EA (1) | EA201791350A9 (es) |
| EC (1) | ECSP17038089A (es) |
| IL (1) | IL252244B (es) |
| JO (1) | JOP20150319B1 (es) |
| MA (1) | MA41176A (es) |
| MX (1) | MX384088B (es) |
| MY (1) | MY194190A (es) |
| NI (1) | NI201700076A (es) |
| PE (2) | PE20171181A1 (es) |
| PH (1) | PH12017501125A1 (es) |
| SG (1) | SG11201704917XA (es) |
| TN (1) | TN2017000255A1 (es) |
| TW (1) | TWI654179B (es) |
| UA (1) | UA125369C2 (es) |
| UY (1) | UY36453A (es) |
| WO (1) | WO2016096843A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108778347A (zh) * | 2016-03-24 | 2018-11-09 | 拜耳制药股份公司 | 放射性药物配合物 |
| WO2017211809A1 (en) * | 2016-06-10 | 2017-12-14 | Bayer Pharma Aktiengesellschaft | Radio-pharmaceutical complexes |
| US20200016283A1 (en) * | 2017-02-24 | 2020-01-16 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| WO2018183906A1 (en) * | 2017-03-30 | 2018-10-04 | Cornell University | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
| CA3110754A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| US20220125960A1 (en) | 2019-02-21 | 2022-04-28 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| CA3130809A1 (en) | 2019-02-22 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
| EP4003959A1 (en) | 2019-07-25 | 2022-06-01 | Bayer AS | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| AU2022210371A1 (en) | 2021-01-22 | 2023-07-20 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158804B2 (en) * | 2007-01-11 | 2012-04-17 | Ge Healthcare As | Chelating agents |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2015
- 2015-12-14 MA MA041176A patent/MA41176A/fr unknown
- 2015-12-15 MX MX2017008093A patent/MX384088B/es unknown
- 2015-12-15 CR CR20170256A patent/CR20170256A/es unknown
- 2015-12-15 PE PE2017001093A patent/PE20171181A1/es unknown
- 2015-12-15 EP EP15813024.5A patent/EP3233137A1/en active Pending
- 2015-12-15 MY MYPI2017702228A patent/MY194190A/en unknown
- 2015-12-15 SG SG11201704917XA patent/SG11201704917XA/en unknown
- 2015-12-15 CU CU2017000082A patent/CU24493B1/es unknown
- 2015-12-15 KR KR1020177016311A patent/KR20170094223A/ko not_active Withdrawn
- 2015-12-15 AU AU2015367722A patent/AU2015367722A1/en not_active Abandoned
- 2015-12-15 TN TN2017000255A patent/TN2017000255A1/en unknown
- 2015-12-15 EA EA201791350A patent/EA201791350A9/ru unknown
- 2015-12-15 BR BR112017012841A patent/BR112017012841A2/pt not_active Application Discontinuation
- 2015-12-15 UA UAA201707516A patent/UA125369C2/uk unknown
- 2015-12-15 US US15/537,127 patent/US20170340759A1/en not_active Abandoned
- 2015-12-15 WO PCT/EP2015/079773 patent/WO2016096843A1/en not_active Ceased
- 2015-12-15 PE PE2022002504A patent/PE20230829A1/es unknown
- 2015-12-15 CA CA2970841A patent/CA2970841A1/en active Pending
- 2015-12-15 JP JP2017532833A patent/JP6821569B2/ja active Active
- 2015-12-15 CN CN201580069545.0A patent/CN107278155B/zh active Active
- 2015-12-16 JO JOP/2015/0319A patent/JOP20150319B1/ar active
- 2015-12-17 UY UY0001036453A patent/UY36453A/es not_active Application Discontinuation
- 2015-12-17 TW TW104142567A patent/TWI654179B/zh active
- 2015-12-17 AR ARP150104130A patent/AR103063A1/es not_active Application Discontinuation
-
2017
- 2017-05-11 IL IL252244A patent/IL252244B/en active IP Right Grant
- 2017-06-15 PH PH12017501125A patent/PH12017501125A1/en unknown
- 2017-06-16 CO CONC2017/0005975A patent/CO2017005975A2/es unknown
- 2017-06-16 CL CL2017001592A patent/CL2017001592A1/es unknown
- 2017-06-16 DO DO2017000143A patent/DOP2017000143A/es unknown
- 2017-06-16 NI NI201700076A patent/NI201700076A/es unknown
- 2017-06-19 EC ECIEPI201738089A patent/ECSP17038089A/es unknown
-
2021
- 2021-01-05 JP JP2021000454A patent/JP7160961B2/ja active Active
- 2021-01-15 US US17/150,811 patent/US20210322583A1/en not_active Abandoned
- 2021-04-29 AU AU2021202665A patent/AU2021202665B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171181A1 (es) | Complejos radiofarmaceuticos | |
| BR112018075554A2 (pt) | complexos radiofarmacêuticos | |
| EA201892119A1 (ru) | Лекарственный препарат, полученный путем комбинирования агониста fxr и arb | |
| MX2016015511A (es) | Compuestos que comprenden grupo auto-destructivo. | |
| AR085665A1 (es) | Fluidos de tratamiento que contienen un agente quelante biodegradable y metodos para su uso | |
| EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
| MX2017003121A (es) | Formulaciones de anticuerpos. | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| EP3501517A4 (en) | ALL-TRANS | |
| CO2018010024A2 (es) | Complejos radiofarmacéuticos | |
| EA201990093A1 (ru) | Двухкомпонентная композиция | |
| TH1701003363A (th) | สารเชิงซ้อนเภสัชรังสี | |
| UA96243U (uk) | Тест-засіб для ідентифікації компонентів екстемпоральних лікарських засобів на основі фільтрувального паперу, модифікованого хромогенним реагентом заліза (ііі) хлоридом |